Clinical Trial Update: Efficacy and Safety of CIP-Isotretinoin in Patients With Severe Recalcitrant Nodular Acne [Phase 3]

View source ↗

Summary

Phase 3 trial results for CIP-Isotretinoin in patients with severe recalcitrant nodular acne show efficacy and safety data. The results were posted on 2014-07-0…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nodular Acne

Drugs mentioned

• CIP-Isotretinoin (isotretinoin)

Snippet

Sponsor: Cipher Pharmaceuticals Inc. | Conditions: Severe Nodular Acne | Phase 3 | Status: COMPLETED | Results posted: 2014-07-04